AL

Alcon Inc.

ALCHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$10.40B
+4.9% YoY
Net Income
$980.0M
-3.7% YoY
EBITDA
$2.70B
+0.9% YoY
Free Cash Flow
$1.27B

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 Below MA1500.7% below MA150
Aug 27CONFIRMED Below MA1500.5% below MA150
MACD Negative CrossoverHistogram -0.1503, negative momentum
About Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. Valued at $33.41B, ALC is a large-cap name in its sector. The company operates through two segments, Surgical and Vision Care.

Where ALC stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, ALC finished 0.70% below its 150-day moving average ($72.75) and 2.76% below its 200-day moving average ($74.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ALC overbought or oversold?

At the September 3, 2026 close, ALC's RSI(14) was 42.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$33.41B
P/E (TTM)52.76
Fwd P/E17.32
EPS$1.31
Beta0.70
52W Change-9.4%
Dividend Yield0.51%
ROE2.9%
Analysis

Alcon Inc. carries $5.30B in total debt against $1.46B in cash reserves — debt is roughly 3.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.27B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $8.72B to $10.40B.

With a beta below 0.7, Alcon Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ALC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms